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•  Human Papillomavirus (HPV) is the most prevalent sexually transmitted infection in the United States.1
•  Although the HPV vaccine has been proven to be effective and safe, the vaccination rates are significantly less 
compared to other vaccines.2
•  In men, HPV infection may lead to the development of numerous forms of cancer including oropharyngeal, 
anal and penile.3
•  According to the 2019 CDC National Immunization Survey, adolescents 13-17 years old were up to date with:2
•  HPV Vaccination: Males (48.7%), Females (53.7%)
•  Tdap Vaccination: 88.9%
•  Varicella Vaccination: 90.8%
•  MMR Vaccination: 91.9%
•  Hep B Vaccination: 92.1%  
Problem Identification
	 Women Men 
Oropharyngeal 2,200 11,300
Cervical 10,900 0
Anal 4,200 2,000
Vulvar 2,800 0
Penile 0 800
Vaginal 600 0
Total 20,700 14,100
Cancer diagnoses related to HPV each year in the United States
2b 
Problem Identification
•  In 2016, sixty-nine NCI-Designed Cancer Centers determined that the low rate of HPV vaccination in the United States is a 
serious public health threat.4
•  According to a report approved by the National Vaccine Advisory Committee in 2015, two significant barriers for HPV 
vaccination were weak and inconsistent provider recommendations and low parental demand.5
•  The graph below demonstrates the relative change in incidence of high-grade cervical lesions by birth cohort 1980-1994 
compared to 1979 in the state of Connecticut most likely due to HPV vaccination.6
•  Similar studies have not been done with male HPV-related cancers in Connecticut.
•  Due to the success of the HPV vaccine in the prevention of cervical cancer, men in the recommended age group should be 
advised to receive the vaccination to prevent oropharyngeal, anal and penile cancers. 
Public Health Costs
•  In the United States, the cost per HPV vaccination is estimated to be $360-$600 per 
person while the average cost of treatment for oropharyngeal cancer $40,463.80. 7, 8
•  Connecticut’s vaccination budget expanded to include the HPV vaccination for 
patients through the Connecticut Vaccine Program (CVP). 
•  “Beginning January 1, 2018, providers can order HPV vaccine for all 11 and 12 year old patients in their 
practice, including those with private insurance.” – Mick Boldue (Vaccine Coordinator – CVP)
•  In 2003, in the United States, the cost of new cases of mouth and oropharyngeal 
cancer related to HPV was estimated to be $38.1 million (range, $17.7-$54 million). 8
•  The cost of the increase in HPV driven cancers in both males and females has been 
greatly underestimated and ignored in the United States and other countries around 
the world.9
•  One study in the United Kingdom demonstrated that the annual cost for HPV related 
oropharyngeal cancer is 80 million dollars while the cost to vaccinate every male would cost between 
25-28 million dollars.9
3 
Community Perspective 
In order to gain a community perspective, I interviewed four medical providers at the Newtown Family 
Medicine Clinic in Newtown, CT about the barriers for HPV vaccination in males and discussed ideas for 
improvement with six other providers in the practice.
•  What do you believe are the major barriers for male patients to receive the HPV vaccination?
•  “Many people do not know that HPV can affect males as well. It is important to educate families that the vaccine is best started before sexual 
activity and to ensure that they understand that getting the vaccine doesn’t imply that the child will start having sex soon” – Dr. Chang MD
•  “The misinformation on social media is a big barrier as well as the lack of knowledge of HPV risks and how it is spread. I think there is 
information that is misrepresented and manipulated against vaccination. The whole thing needs to be broken down and explained properly, 
including the science behind the new evidence, risks, rewards, links to cancer, etc.” – Hannah Fischetto - Medical Assistant 
•  “One big challenge for males to get vaccinated is that many times their families believe that only females need it since males do not have a cervix 
therefore are not at risk for cervical cancer. It is important that males are educated on HPV related cancers in men and future prevention for 
their partners.”   – Ms. Khuen – APRN
•  “Many parents do not understand how their son can get HPV and the role in transmission they may have” – Kathleen D’Orso APRN
•  Ideas on how to improve the understanding of the importance of HPV vaccination after speaking with 
multiple medical providers at Newtown Family Medicine. 
•  Many providers mentioned that a pamphlet to educate a parent before the HPV vaccination is advised would be very helpful and informative.
•  We discussed that making various resources available for patients including educational literature, YouTube advertisements and commercials 
would help more parents understand the importance of vaccination. 
4 
5a 
•  A survey was created and given to medical providers at Newtown Family Medicine to aid in understanding the perceived 
barriers to HPV vaccination in Newtown, CT, in order to create an appropriate brochure for the clinic. 
Intervention
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Two	doses	of	the	HPV	vaccine	are	
recommended	for	all	boys	and	
girls	at	ages	11-12	
	
	
	
	
	
	
Recommended	for	everyone	
through	age	26	years,	if	not	
vaccinated	already	
	
• If	vaccines	are	started	after	age	
15,	three	shots	are	given	over	
six	months	
 
	
	
For	more	information:	
	
Visit	
www.cdc.gov/hpv/parents/vaccine.html	
and	ask	your	doctor	
 
 
 
 
 
 
	
	
	
	
	
Newtown	Primary	Care	
170	Mount	Pleasant	Rd	
Newtown,	CT	06470	
Phone:	(203)	426-1818	
Fax:	(203)	426-8253	
 
	
	
Dose	#2	
6-12	months	after	
the	first	dose	
Dose	#1	
11-	12	years	
•  With insight provided by the survey, a trifold brochure was designed using data provided by the CDC regarding HPV vaccination.
•  The brochures were given to providers and patients as well as placed in rooms around the Newtown Family Medicine Clinic.  
Intervention
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
	
80%	of	people	will	get	an	HPV	infection	
in	their	lifetime	
• About	 14	million	Americans	 become	
infected	with	HPV	each	year	
	
HPV	vaccination	prevents	cancer	
• HPV	 is	 estimated	 to	 cause	 nearly	
35,000	 cases	 of	 cancer	 in	 men	 and	
women	each	year	in	the	US		
	
HPV	 vaccination	 has	 proven	 to	 be	 safe	
and	 effective	 at	 providing	 long-lasting	
protection	
• Over	 100	 million	 doses	 have	 been	
distributed	in	 the	United	States	with	
a	 proven	 safety	 record	with	 over	 10	
years	of	monitoring	
Vaccines	protect	your	
child	before	exposure	to	
the	disease.	That	is	why	
it	is	recommended	that	
your	child	is	vaccinated	
earlier	rather	than	later,	
long	before	they	are	
exposed	to	HPV	
 
	
Boys	can	develop	HPV	cancers	as	adults	
HPV	does	not	only	affect	females.	
Approximately	4	out	of	10	cases	of	cancer	
caused	by	HPV	occur	among	men.	
	
	 Women	 Men	
Back	of	throat	 2,200	 11,300	
Cervical	 10,900	 0	
Anal	 4,200	 2,000	
Vulvar	 2,800	 0	
Penile	 0	 800	
Vaginal	 600	 0	
Total	 20,700	 14,100	
	
How	many	cancers	are	linked	with	HPV	each	year?	
 
HPV	vaccination	can	prevent	up	to	90%	of	HPV	
cancers	
Information	from	this	
brochure	can	be	found	at:	
www.cdc.gov/hpv/parents
/vaccine.html	
	
Results
•  The HPV vaccination brochures were placed in the lobby and various rooms in the family medicine clinic for patients, 
parents and providers to read. 
•  100% of the medical providers surveyed at the Newtown Family Medicine practice believe that the brochure will help 
families make an educated decision regarding HPV vaccination of their child. 
•  According to the medical providers at Newtown Family Medicine, the most common reasons parents deny HPV 
vaccination for their children are:
•  Believe they are too young to get HPV (5 medical providers)
•  Think the vaccine may be harmful (5 medical providers)
•  Believe the vaccine is only for females (2 medical providers)
•  Not enough evidence to support the benefits (0 medical providers)
•  Not enough time during the visit to discuss fully (0 medical providers)
•  The perceived estimation of HPV vaccination vs. the actual proportion of children and adolescents vaccinated for HPV 
according to the survey done by 12 Newtown Family Medicine medical providers (medical assistant, MD, APRN, PA)
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Results
Perceived Vaccination rates:
•  Males: 44.4% ± 17%
•  Females: 66.7% ± 10%
Actual Vaccination rates
•  Males: 48.7%
•  Females 53.7%
Conclusion
There is no significant difference between the perceived male 
vaccination rates and the actual value demonstrating that 
medical providers at Newtown Family Medicine have an 
accurate understanding on the under vaccination of male 
patients. However, the medical providers in the clinic 
overestimated the amount of females vaccinated for HPV on 
average by 13%.
Effectiveness and Limitations
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•  The effectiveness of this intervention will be determined in future months by the proportion of 
males receiving the HPV vaccine due to the information provided by the brochure.
•  Future assessment of effectiveness 
•  A survey to patients in the clinic regarding their perception of HPV vaccination for both males and females before and after 
reading the brochure. 
•  A survey to providers to evaluate if they were more likely to speak with patients regarding HPV vaccination during the 
encounter if the brochure was in the room. 
•  Determine if the presence of the brochure in the clinic, increased interest in HPV vaccination.
•  Limitations of the project
•  The effectiveness of the brochure is dependent on its availably for patients.
•  Due to limited time constraints, follow up on the effectiveness of the brochure in the clinic could not be evaluated. 
•  Patients may have strong beliefs toward HPV vaccination that may not change due to the information provided in the 
brochure. 
 
Future Projects
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•  Distribute brochures to other Family Medicine and Pediatric clinics in 
Fairfield County, CT. 
•  Compile data on the effectiveness of the brochure in increasing HPV 
vaccination rates in both male and female patients. 
•  Collect data regarding HPV-related cancers in males in Connecticut and 
determine if vaccination has led to a similar decrease seen in cervical cancer 
for females. 
•  Share the results of the survey with other providers in order to highlight 
common misconceptions and barriers to vaccinate children for HPV in 
Connecticut. 
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